美股异动 | DBV Technologies盘前大涨超30% 4-7岁花生过敏贴片三期试验取得积极结果

Group 1 - DBV Technologies experienced a pre-market surge of over 30% following positive preliminary results from the Phase 3 VITESSE trial of the VIASKIN peanut patch in children aged 4-7 with peanut allergies, achieving its primary endpoint [1] - The Biologics License Application (BLA) submission for the 4-7 age group is scheduled for the first half of 2026 [1] Group 2 - The pre-market price of DBV Technologies reached $23.400, reflecting an increase of $5.420 or 30.14% [2] - The closing price prior to the announcement was $17.980, with a trading volume of 867,400 shares [2] - The company's total market capitalization stands at $722 million, with a total share count of 40.1336 million [2]